BUB1 Immunolocalization in Breast Carcinoma: Its Nuclear Localization as a Potent Prognostic Factor of the Patients

Hormones and Cancer

Volumn 4, Issue 2, 2013, Pages 92-102

  Takagi, Kiyoshi ^a   Miki, Yasuhiro ^a   Shibahara, Yukiko ^a   Nakamura, Yasuhiro ^a   Ebata, Akiko ^a   Watanabe, Mika ^b   Ishida, Takanori ^a   Sasano, Hironobu ^a,b   Suzuki, Takashi ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b TOHOKU UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BUB1 RELATED PROTEIN; KI 67 ANTIGEN;

ADULT; ARTICLE; BREAST CARCINOMA; CANCER PROGNOSIS; CANCER SPECIFIC SURVIVAL; CANCER STAGING; CANCER SURGERY; CANCER TISSUE; CARCINOMA CELL; CELL PROLIFERATION; DISTANT METASTASIS; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOLOCALIZATION; IMMUNOREACTIVITY; LABELING INDEX; LYMPH NODE METASTASIS; M PHASE CELL CYCLE CHECKPOINT; MICROARRAY ANALYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION;

EID: 84874411973     PISSN: 18688497     EISSN: 18688500     Source Type: Journal    
DOI: 10.1007/s12672-012-0130-x     Document Type: Article

References (39)

1. Hüsemann Y, Geigl JB, Schubert F, Musiani P, Meyer M, Burghart E, Forni G, Eils R, Fehm T, Riethmüller G et al (2008) Systemic spread is an early step in breast cancer. Cancer Cell 13: 58-68.
2. van Diest PJ, van der Wall E, Baak JP (2004) Prognostic value of proliferation in invasive breast cancer: a review. J Clin Pathol 57: 675-681.
3. de Azambuja E, Cardoso F, de Castro G Jr, Colozza M, Mano MS, Durbecq V, Sotiriou C, Larsimont D, Piccart-Gebhart MJ, Paesmans M (2007) Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12, 155 patients. Br J Cancer 96: 1504-1513.
4. Sherr CJ (1996) Cancer cell cycles. Science 274: 1672-1677.
5. Molinari M (2000) Cell cycle checkpoints and their inactivation in human cancer. Cell Prolif 33: 261-274.
6. Musacchio A (2011) Spindle assembly checkpoint: the third decade. Philos Trans R Soc Lond B Biol Sci 366: 3595-3604.
7. Mondal G, Sengupta S, Panda CK, Gollin SM, Saunders WS, Roychoudhury S (2007) Overexpression of Cdc20 leads to impairment of the spindle assembly checkpoint and aneuploidization in oral cancer. Carcinogenesis 28: 81-92.
8. Williams GL, Roberts TM, Gjoerup OV (2007) Bub1: escapades in a cellular world. Cell Cycle 6: 1699-1704.
9. Cahill DP, Lengauer C, Yu J, Riggins GJ, Willson JK, Markowitz SD, Kinzler KW, Vogelstein B (1998) Mutations of mitotic checkpoint genes in human cancers. Nature 392: 300-303.
10. Haruki N, Saito H, Harano T, Nomoto S, Takahashi T, Osada H, Fujii Y, Takahashi T (2001) Molecular analysis of the mitotic checkpoint genes BUB1, BUBR1 and BUB3 in human lung cancers. Cancer Lett 162: 201-205.
11. Olesen SH, Thykjaer T, Ørntoft TF (2001) Mitotic checkpoint genes hBUB1, hBUB1B, hBUB3 and TTK in human bladder cancer, screening for mutations and loss of heterozygosity. Carcinogenesis 22: 813-815.
12. Shigeishi H, Yokozaki H, Kuniyasu H, Nakagawa H, Ishikawa T, Tahara E, Yasui W (2001) No mutations of the Bub1 gene in human gastric carcinomas. Oncol Rep 8: 791-794.
13. Ouyang B, Knauf JA, Ain K, Nacev B, Fagin JA (2002) Mechanisms of aneuploidy in thyroid cancer cell lines and tissues: evidence for mitotic checkpoint dysfunction without mutations in BUB1 and BUBR1. Clin Endocrinol (Oxf) 56: 341-350.
14. Yuan B, Xu Y, Woo JH, Wang Y, Bae YK, Yoon DS, Wersto RP, Tully E, Wilsbach K, Gabrielson E (2006) Increased expression of mitotic checkpoint genes in breast cancer cells with chromosomal instability. Clin Cancer Res 12: 405-410.
15. Shigeishi H, Yoneda S, Taki M, Nobumori T, Ohta K, Higashikawa K, Yasui W, Kamata N (2006) Correlation of human Bub1 expression with tumor-proliferating activity in salivary gland tumors. Oncol Rep 15: 933-938.
16. Grabsch HI, Askham JM, Morrison EE, Pomjanski N, Lickvers K, Parsons WJ, Boecking A, Gabbert HE, Mueller W (2004) Expression of BUB1 protein in gastric cancer correlates with the histological subtype, but not with DNA ploidy or microsatellite instability. J Pathol 202: 208-214.
17. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M et al. (2010) American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. 134: e48-72.
18. Miki Y, Suzuki T, Kitada K, Yabuki N, Shibuya R, Moriya T, Ishida T, Ohuchi N, Blumberg B, Sasano H (2006) Expression of the steroid and xenobiotic receptor and its possible target gene, organic anion transporting polypeptide-A, in human breast carcinoma. Cancer Res 66: 535-542.
19. Nagasaki S, Suzuki T, Miki Y, Akahira J, Kitada K, Ishida T, Handa H, Ohuchi N, Sasano H (2009) 17β-Hydroxysteroid dehydrogenase type 12 in human breast carcinoma: a prognostic factor via potential regulation of fatty acid synthesis. Cancer Res 69: 1392-1399.
20. Gao Y, Niu Y, Wang X, Wei L, Zhang R, Lv S, Yu Q, Yang X (2011) Chromosome aberrations associated with centrosome defects: a study of comparative genomic hybridization in breast cancer. Hum Pathol 42: 1693-1701.
21. Gerdes J, Schwab U, Lemke H, Stein H (1983) Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer 31: 13-20.
22. Liu T, Niu Y, Yu Y, Liu Y, Zhang F (2009) Increased gamma-tubulin expression and P16INK4A promoter methylation occur together in preinvasive lesions and carcinomas of the breast. Ann Oncol 20: 441-448.
23. Shigeishi H, Oue N, Kuniyasu H, Wakikawa A, Yokozaki H, Ishikawa T, Yasui W (2001) Expression of Bub1 gene correlates with tumor proliferating activity in human gastric carcinomas. Pathobiology 69: 24-29.
24. Grabsch H, Takeno S, Parsons WJ, Pomjanski N, Boecking A, Gabbert HE, Mueller W (2003) Overexpression of the mitotic checkpoint genes BUB1, BUBR1, and BUB3 in gastric cancer-association with tumour cell proliferation. J Pathol 200: 16-22.
25. Wu CW, Chi CW, Huang TS (2004) Elevated level of spindle checkprotein MAD2 correlates with cellular mitotic arrest, but not with aneuploidy and clinicopathological characteristics in gastric cancer. World J Gastroenterol 10: 3240-3244.
26. Han S, Park K, Kim HY, Lee MS, Kim HJ, Kim YD, Yuh YJ, Kim SR, Suh HS (2000) Clinical implication of altered expression of Mad1 protein in human breast carcinoma. Cancer 88: 1623-1632.
27. Shin HJ, Baek KH, Jeon AH, Park MT, Lee SJ, Kang CM, Lee HS, Yoo SH, Chung DH, Sung YC et al (2003) Dual roles of human BubR1, a mitotic checkpoint kinase, in the monitoring of chromosomal instability. Cancer Cell 4: 483-497.
28. Li GQ, Zhang HF (2004) Mad2 and p27 expression profiles in colorectal cancer and its clinical significance. World J Gastroenterol 10: 3218-3220.
29. Tanaka K, Nishioka J, Kato K, Nakamura A, Mouri T, Miki C, Kusunoki M, Nobori T (2001) Mitotic checkpoint protein hsMAD2 as a marker predicting liver metastasis of human gastric cancers. Jpn J Cancer Res 92: 952-958.
30. Burum-Auensen E, Deangelis PM, Schjølberg AR, Røislien J, Andersen SN, Clausen OP (2007) Spindle proteins Aurora A and BUB1B, but not Mad2, are aberrantly expressed in dysplastic mucosa of patients with longstanding ulcerative colitis. J Clin Pathol 60: 1403-1408.
31. Warren CD, Brady DM, Johnston RC, Hanna JS, Hardwick KG, Spencer FA (2002) Distinct chromosome segregation roles for spindle checkpoint proteins. Mol Biol Cell 13: 3029-3041.
32. Gao F, Ponte JF, Levy M, Papageorgis P, Cook NM, Ozturk S, Lambert AW, Thiagalingam A, Abdolmaleky HM, Sullivan BA et al (2009) hBub1 negatively regulates p53 mediated early cell death upon mitotic checkpoint activation. Cancer Biol Ther 8: 548-556.
33. Bourdeau V, Deschênes J, Métivier R, Nagai Y, Nguyen D, Bretschneider N, Gannon F, White JH, Mader S (2004) Genomewide identification of high-affinity estrogen response elements in human and mouse. Mol Endocrinol 18: 1411-1427.
34. Frasor J, Danes JM, Komm B, Chang KC, Lyttle CR, Katzenellenbogen BS (2003) Profiling of estrogen up- and down-regulated gene expression in human breast cancer cells: insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype. Endocrinol 144: 4562-4574.
35. Ebata A, Suzuki T, Takagi K, Miki Y, Onodera Y, Nakamura Y, Fujishima F, Ishida K, Watanabe M, Tamaki K et al (2012) Oestrogen-induced genes in ductal carcinoma in situ: their comparison with invasive ductal carcinoma. Endocr Relat Cancer 19: 485-496.
36. Dai H, van't Veer L, Lamb J, He YD, Mao M, Fine BM, Bernards R, van de Vijver M, Deutsch P, Sachs A et al (2005) A cell proliferation signature is a marker of extremely poor outcome in a subpopulation of breast cancer patients. Cancer Res 65: 4059-4066.
37. Suzuki S, Takagi K, Miki Y, Onodera Y, Akahira J, Ebata A, Ishida T, Watanabe M, Sasano H, Suzuki T (2012) Nucleobindin 2 in human breast carcinoma as a potent prognostic factor. Cancer Sci 103: 136-143.
38. Morishita M, Sumi T, Nakano Y, Teramae M, Fukuda T, Nobeyama H, Yoshida H, Matsumoto Y, Yasui T, Ishiko O (2012) Expression of mitotic-arrest deficiency 2 predicts the efficacy of neoadjuvant chemotherapy for locally advanced uterine cervical cancer. Exp Ther Med 3: 341-346.
39. Colombo R, Caldarelli M, Mennecozzi M, Giorgini ML, Sola F, Cappella P, Perrera C, Depaolini SR, Rusconi L, Cucchi U et al (2010) Targeting the mitotic checkpoint for cancer therapy with NMS-P715, an inhibitor of MPS1 kinase. Cancer Res 70: 10255-10264.